Personalized Cancer Vaccine Shows Long-Term Promise
Quick Summary Moderna and Merck’s experimental personalized cancer vaccine (mRNA‑based) plus an immune checkpoint inhibitor showed long‑term benefit in high‑risk melanoma. Five‑year Phase 2b data (KEYNOTE‑942) showed the combination reduced the risk of distant spread by 59%, lowered recurrence or death risk by 49%, and improved overall survival (92.2% vs
June 8, 2026
No Comments
